Cutaneous adverse reactions to anti-PD-1 treatment - a systematic review

Anne Birgitte Simonsen; Jeanette Kaae; Eva Ellebaek Steensgaard; Inge Marie Svane; Claus Zachariae

doi:10.1016/j.jaad.2020.04.058

Cutaneous adverse reactions to anti-PD-1 treatment - a systematic review

Anne Birgitte Simonsen, Jeanette Kaae, Eva Ellebaek Steensgaard, Inge Marie Svane, Claus Zachariae

37 Citationer (Scopus)

Abstract

The use of the humanized monoclonal anti-programmed cell death-1 antibodies pembrolizumab and nivolumab as potent anti-cancer therapies is rapidly increasing. However, since their approval numerous cases of cutaneous reactions have been reported. Cutaneous adverse reactions to these agents have yet to be fully characterized and range from non-specific eruptions to recognizable skin manifestations, which may be localized and vary from mild to life-threatening. This systematic review article provides an overview of the various adverse cutaneous reactions to pembrolizumab and nivolumab therapy and offers suggestions for their management.

Originalsprog	Engelsk
Tidsskrift	Journal of the American Academy of Dermatology
Vol/bind	83
Udgave nummer	5
Sider (fra-til)	1415-1424
Antal sider	10
ISSN	0190-9622
DOI	https://doi.org/10.1016/j.jaad.2020.04.058
Status	Udgivet - 1 nov. 2020

Adgang til dokumentet

10.1016/j.jaad.2020.04.058

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{518eaa0548714aeab2492a594b2712df,

title = "Cutaneous adverse reactions to anti-PD-1 treatment - a systematic review",

abstract = "The use of the humanized monoclonal anti-programmed cell death-1 antibodies pembrolizumab and nivolumab as potent anti-cancer therapies is rapidly increasing. However, since their approval numerous cases of cutaneous reactions have been reported. Cutaneous adverse reactions to these agents have yet to be fully characterized and range from non-specific eruptions to recognizable skin manifestations, which may be localized and vary from mild to life-threatening. This systematic review article provides an overview of the various adverse cutaneous reactions to pembrolizumab and nivolumab therapy and offers suggestions for their management.",

keywords = "anti–PD-1, cutaneous adverse reaction, dermatology, immunotherapy, oncology",

author = "Simonsen, {Anne Birgitte} and Jeanette Kaae and {Ellebaek Steensgaard}, Eva and Svane, {Inge Marie} and Claus Zachariae",

year = "2020",

month = nov,

day = "1",

doi = "10.1016/j.jaad.2020.04.058",

language = "English",

volume = "83",

pages = "1415--1424",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby, Inc",

number = "5",

}

TY - JOUR

T1 - Cutaneous adverse reactions to anti-PD-1 treatment - a systematic review

AU - Simonsen, Anne Birgitte

AU - Kaae, Jeanette

AU - Ellebaek Steensgaard, Eva

AU - Svane, Inge Marie

AU - Zachariae, Claus

PY - 2020/11/1

Y1 - 2020/11/1

N2 - The use of the humanized monoclonal anti-programmed cell death-1 antibodies pembrolizumab and nivolumab as potent anti-cancer therapies is rapidly increasing. However, since their approval numerous cases of cutaneous reactions have been reported. Cutaneous adverse reactions to these agents have yet to be fully characterized and range from non-specific eruptions to recognizable skin manifestations, which may be localized and vary from mild to life-threatening. This systematic review article provides an overview of the various adverse cutaneous reactions to pembrolizumab and nivolumab therapy and offers suggestions for their management.

AB - The use of the humanized monoclonal anti-programmed cell death-1 antibodies pembrolizumab and nivolumab as potent anti-cancer therapies is rapidly increasing. However, since their approval numerous cases of cutaneous reactions have been reported. Cutaneous adverse reactions to these agents have yet to be fully characterized and range from non-specific eruptions to recognizable skin manifestations, which may be localized and vary from mild to life-threatening. This systematic review article provides an overview of the various adverse cutaneous reactions to pembrolizumab and nivolumab therapy and offers suggestions for their management.

KW - anti–PD-1

KW - cutaneous adverse reaction

KW - dermatology

KW - immunotherapy

KW - oncology

UR - http://www.scopus.com/inward/record.url?scp=85087662939&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2020.04.058

DO - 10.1016/j.jaad.2020.04.058

M3 - Review

C2 - 32320766

SN - 0190-9622

VL - 83

SP - 1415

EP - 1424

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 5

ER -

Cutaneous adverse reactions to anti-PD-1 treatment - a systematic review

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater